Morgan Stanley
ACXP icon

Morgan Stanley’s Acurx Pharmaceuticals ACXP Stock Holding History

Morgan Stanley’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
7,500
+1,000
+15% +$2.08K ﹤0.01% 6996
2026
Q1 		$24.1K Hold
6,500
– – ﹤0.01% 6656
2025
Q4 		$16.2K Buy
6,500
+1,190
+22% +$5.71K ﹤0.01% 6759
2025
Q3 		$22.8K Hold
5,310
– – ﹤0.01% 6648
2025
Q2 		$54.2K Hold
5,310
– – ﹤0.01% 6331
2025
Q1 		$41.4K Hold
5,310
– – ﹤0.01% 6333
2024
Q4 		$86.4K Buy
5,310
+3,000
+130% +$90.3K ﹤0.01% 6111
2024
Q3 		$87.8K Sell
2,310
-10
-0.4% -$423 ﹤0.01% 6054
2024
Q2 		$104K Buy
2,320
+1,000
+76% +$44K ﹤0.01% 5942
2024
Q1 		$64.7K Buy
1,320
+510
+63% +$33.1K ﹤0.01% 6128
2023
Q4 		$62K Buy
810
+60
+8% +$4.53K ﹤0.01% 6093
2023
Q3 		$22.5K Buy
+750
New +$28.7K ﹤0.01% 6443
2022
Q1 		– Hold
0
– – – 7939
2021
Q4 		– Hold
0
– – – 7954

Other funds holding ACXP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Morgan Stanley's ACXP Position: Q2 2026 in Review

Morgan Stanley increased its Acurx Pharmaceuticals (ACXP) stake by 15% in Q2 2026, buying an estimated $2.08K and bringing the position to 7,500 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6996.

Morgan Stanley first reported a position in ACXP in Q3 2023 and has held it in 12 quarters since. The position peaked at $104K in Q2 2024. 18 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

  • Morgan Stanley held 7,500 shares of Acurx Pharmaceuticals worth $11.6K as of Q2 2026.
  • Morgan Stanley bought 1,000 Acurx Pharmaceuticals shares in Q2 2026, an estimated $2.08K.
  • Acurx Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6996 holding.
  • Morgan Stanley first reported a position in Acurx Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Morgan Stanley's Acurx Pharmaceuticals position peaked at $104K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.